PERRY V. HALUSHKA, M.D., Ph.D.; HULDA WOHLTMANN, M.D.; PHILIP J. PRIVITERA, Ph.D.; GILBERT HURWITZ, M.D.; HARRY S. MARGOLIUS, M.D., Ph.D.
HALUSHKA PV, WOHLTMANN H, PRIVITERA PJ, HURWITZ G, MARGOLIUS HS. Bartter's Syndrome: Urinary Prostaglandin E-like Material and Kallikrein; Indomethacin Effects. Ann Intern Med. 1977;87:281-286. doi: 10.7326/0003-4819-87-3-281
Download citation file:
Published: Ann Intern Med. 1977;87(3):281-286.
The urinary excretions of prostaglandin E-like material (iPGE) and kallikrein were measured in two children with Bartter's syndrome. Urinary iPGE excretion was three and 10 times greater than normal, and urinary kallikrein was five and 10 times greater than normal in the two subjects. Furthermore, excretions of iPGE and kallikrein were highly correlated (P < 0.005) with each other before and during treatment with indomethacin, a prostaglandin synthetase inhibitor. Indomethacin significantly (P < 0.001) reduced urinary iPGE, urinary kallikrein, and plasma renin activity, while increasing the sensitivity to intravenous angiotensin II and the serum potassium to normal. The results confirm that renal prostaglandins may be involved in the pathogenesis of Bartter's syndrome and suggest that renal prostaglandins and the kallikrein-kinin system are linked.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Adrenal Disorders.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only